International guidelines now recommend the use of neoadjuvant chemoimmunotherapy for eligible patients with resectable NSCLC who are planned for surgical resection.1,2

WHY THE NEED FOR CHANGE?

Nearly 6 in 10 patients with early-stage NSCLC experience recurrence or death within 5 years of complete surgical resection3

Following complete resection of NSCLC in a pooled analysis of >4,500 patients:3^*

WHAT’S THE ROLE OF NEOADJUVANT IMMUNO-ONCOLOGY?

Immuno-oncology (IO) in combination with chemotherapy in the neoadjuvant setting:

^Staging based on AJCC 7th edition. *This population included 347 patients with Stage IA resectable NSCLC, of which 37% experienced recurrence or death by 5 years.3

IS YOUR MDT READY FOR THIS CHANGE?

Ensure all of your early stage resectable NSCLC patients are discussed at a multidisciplinary (MDT) team meeting before initiating any treatment plan.

LEARN MORE ABOUT THE CHANGING LANDSCAPE TODAY   

AJCC = American Joint Committee on Cancer; NSCLC = non-small cell lung cancer.

References: 1. ASCO Guidelines. Management of Stage III Non-Small Cell Lung Cancer – Rapid Recommendation Update: posted on June 4, 2023. Available at: old-prod.asco.org/practice-patients/guidelines/thoracic-cancer#/168762. Accessed October 2023. 2. Ettinger et al. NCCN Guidelines® Insights – Non-Small Cell Lung Cancer, Version 2.2023. 3. Pignon et al. J Clin Oncol 2008;26:3552–9. 4. Topalian et al. Science 2020;367(6477):eaax0182. 5. O’Donnell et al. Clin Cancer Res 2019;25:5743–51. 6. Galluzzi et al. Nat Rev Drug Discov 2012;11:215–3.

This website is intended for Australian Healthcare Professionals.

© 2023 Bristol-Myers Squibb. BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd,
ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3160. ONC-AU-2300171. November 2023. BRMSOY0111.